Inhibitor Therapeutics, Inc. (INTI)

Market Cap	15.19M -1.0%
Revenue (ttm)	n/a
Net Income	-3.43M
EPS	-0.02
Shares Out	172.57M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	150
Average Volume	43,776
Open	0.0880
Previous Close	n/a
Day's Range	0.0880 - 0.0880
52-Week Range	0.0338 - 0.1229
Beta	-0.36
RSI	52.35
Earnings Date	Mar 27, 2026

About Inhibitor Therapeutics

Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. It engages in the development of therapies for prostate and lung cancer utilizing itraconazole; and conducted a positive Phase 2b clinical trial of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome. The company was formerly known as HedgePath Pharmaceuticals, Inc. and changed its name to Inhibitor Therapeutics, Inc. ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1992
• Employees: 9
• Stock Exchange: OTCMKTS
• Ticker Symbol: INTI